Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE DIPROPIONATE versus DULERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE DIPROPIONATE versus DULERA.
BETAMETHASONE DIPROPIONATE vs DULERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone dipropionate is a glucocorticoid receptor agonist that binds to cytosolic glucocorticoid receptors, leading to modulation of gene transcription. It suppresses pro-inflammatory cytokines (e.g., IL-1, IL-2, TNF-α), inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes mast cells.
DULERA is a combination of formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), and mometasone furoate, a corticosteroid. Formoterol acts by relaxing bronchial smooth muscle via beta2-receptor activation. Mometasone furoate reduces inflammation in the lungs by inhibiting inflammatory mediators and suppressing immune responses.
Apply topically as 0.05% cream, ointment, or lotion to affected area once or twice daily. Maximum: 45 g/week.
Inhalation: 2 inhalations twice daily (morning and evening). Each inhalation delivers mometasone furoate 100/200 mcg and formoterol fumarate 5 mcg.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (parenteral); clinically, duration of adrenal suppression may extend beyond this.
Formoterol: terminal half-life 10-14 hours (supports twice-daily dosing); Mometasone: terminal half-life 13.8 hours (range 10-20 hours) after inhalation.
Renal, ~75% as conjugated metabolites; biliary/fecal, ~25%.
Formoterol: 10-15% renal as unchanged drug and metabolites, remainder hepatically cleared; Mometasone: >99% biliary/fecal as metabolites, <1% renal unchanged.
Category D/X
Category C
Corticosteroid
Corticosteroid/Beta2-Agonist Combination